Inclusion Criteria:

          -  Locally advanced or metastatic non-secretory breast cancer, lung cancer, melanoma, and
             colorectal cancer with unknown human neurotrophic tyrosine receptor kinase 1 (NTRK1),
             NTRK2, or NTRK3 fusion status.

          -  Subjects must have received prior standard therapy appropriate for their tumor type
             and stage of disease, or in the opinion of the investigator, would be unlikely to
             tolerate or derive clinically meaningful benefit from appropriate standard of care
             therapy.

          -  Subjects must have at least one measurable lesion as defined by Response Evaluation
             Criteria in Solid Tumors (RECIST) v1.1.

        Exclusion Criteria:

          -  Prior progression while receiving approved or investigational tyrosine kinase
             inhibitors targeting tropomyosin receptor kinase (TRK). Subjects who received less
             than 28 days of treatment and discontinued because of intolerance or toxicity are
             eligible.

          -  Symptomatic or unstable brain metastases. (Note: Subjects with asymptomatic brain
             metastases are eligible to participate in the study.) Subjects with primary central
             nervous system (CNS) tumors are eligible.

          -  Pregnancy or lactation.

          -  Active uncontrolled systemic bacterial, viral, or fungal infection Common Terminology
             Criteria for Adverse Events(CTCAE) grade ≥ 2; unstable cardiovascular disease, or
             other systemic disease that would limit compliance with study procedures.

          -  Unstable cardiovascular disease is defined as:

               -  In adults, persistently uncontrolled hypertension defined as systolic blood
                  pressure (BP) > 150 mmHg and/or diastolic BP > 100 mmHg despite antihypertensive
                  therapy.

               -  Myocardial infarction within 3 months of screening.

               -  Stroke within 3 months of screening.